-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
-
Summary
-
Calidi Biotherapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and change rate from Q4 2021 to Q2 2023.
- Calidi Biotherapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Jun 2023 was $870.000.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)